IFN-β1a (recombinant human)

Home
Ligands
IFN-β1a (recombinant human)

Ligand id: 8339

Name: IFN-β1a (recombinant human)

Summary
Biological activity
Clinical data
References
Structure
Similar ligands

Classification
Compound class	Peptide or derivative
Approved drug?	Yes (source: FDA (1996))

International Nonproprietary Names
INN number	INN
5380	interferon beta

Synonyms
Avonex®
Rebif®

Synonyms

Avonex®

Rebif®

Database Links
DrugBank Ligand	DB00060
Search PubMed clinical trials	interferon beta
Search PubMed titles	interferon beta
Search PubMed titles/abstracts	interferon beta
Wikipedia	Interferon_beta_1a

Comments
Compared to the sequence of the endogenous peptide, IFN-β1a has a Gln to Cys substitution at position 17 and retains the Asn glycosylation site at position 80. Whilst the regular form of this peptide has to be injected 1-3 times/week, a PEGylated form (peginterferon beta-1a) is now available that requires less frequent administration (on a fortnightly basis).

Comments

Compared to the sequence of the endogenous peptide, IFN-β1a has a Gln to Cys substitution at position 17 and retains the Asn glycosylation site at position 80. Whilst the regular form of this peptide has to be injected 1-3 times/week, a PEGylated form (peginterferon beta-1a) is now available that requires less frequent administration (on a fortnightly basis).